Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. director Daniel Tasse reported new equity awards. He received 9,807 shares of common stock through a time-based restricted stock unit grant, which will vest in full on May 29, 2027 if he remains in continuous service.
He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these awards, he directly holds 28,861 shares of common stock. These are compensation-related grants, not open-market purchases or sales.
REGENXBIO Inc. director David C. Stump reported equity compensation awards, not open-market purchases. He received 9,807 shares of common stock underlying a time-based restricted stock unit that will vest on May 29, 2027, subject to his continuous service to the company.
He was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. Following these awards, he holds 28,861 shares of common stock directly.
REGENXBIO Inc. director Jennifer Zachary reported equity awards from the company. She received 9,807 shares of common stock in the form of a time-based restricted stock unit award that will fully vest on May 29, 2027, subject to continued service. Following this grant, she directly holds 31,871 common shares. She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which will vest on May 29, 2027 and expire on May 29, 2036.
REGENXBIO Inc. director Kenneth T. Mills reported equity awards consisting of restricted stock units and stock options. On May 29, 2026, he received 9,807 shares of common stock through a time-based restricted stock unit award that carries no cash exercise price. These RSUs are scheduled to vest 100% on May 29, 2027, conditioned on his continuous service to the company. On the same date, he was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share, which are likewise scheduled to vest on May 29, 2027, subject to continued service. Following the stock grant, Mills directly held 495,925 shares of REGENXBIO common stock.
REGENXBIO Inc. director George V. Migausky reported equity awards that increase his stake in the company. He received 9,807 shares of common stock as a time-based restricted stock unit award that will fully vest on May 29, 2027, contingent on continued service. Following this award, he directly holds 28,861 common shares. He was also granted stock options for 46,600 shares of common stock at an exercise price of $7.01 per share, which vest on May 29, 2027 and expire on May 29, 2036. These are compensation-related grants rather than open-market purchases or sales.
REGENXBIO Inc. director Argeris N. Karabelas received new equity awards as part of his compensation. He was granted 9,807 shares of common stock through a time-based restricted stock unit award that will fully vest on May 29, 2027, provided he continues to serve the company.
He also received stock options for 46,600 shares of common stock at an exercise price of $7.01 per share. These options begin vesting in 12 equal monthly installments after May 29, 2027 and expire on May 29, 2036. Following the RSU grant, he directly owns 28,861 shares of REGENXBIO common stock.
REGENXBIO Inc. reported that director Alexandra Glucksmann received new equity awards. She was granted 9,807 shares of Common Stock in the form of a time-based restricted stock unit award, which will vest 100% on May 29, 2027 if she continues service with the company.
She was also granted stock options covering 46,600 shares of Common Stock at an exercise price of $7.01 per share. These options will vest on May 29, 2027 and expire on May 29, 2036. Following the grants, she directly holds 28,861 Common Stock shares and 46,600 options. These are compensation awards rather than open-market purchases or sales.
REGENXBIO Inc. director Allan M. Fox reported new equity awards and updated indirect holdings. He received 9,807 shares of common stock as a time-based restricted stock unit grant, with all shares scheduled to vest on May 29, 2027, subject to continuous service.
He was also granted stock options for 46,600 shares at an exercise price of $7.01 per share, vesting on May 29, 2027 and expiring on May 29, 2036. Following these grants, he directly holds 28,861 common shares.
The filing also lists indirect holdings of common stock through entities including Quaker Gray LLC with 1,529,981 shares, HBF Gift Trust LLC with 315,000 shares, AMF Gift Trust LLC with 315,000 shares, and AMF Family Gift Trust LLC with 722,485 shares, with beneficial ownership of these indirect positions disclaimed except for his indirect pecuniary interest.
REGENXBIO Inc. director Jean Bennett received new equity awards as part of compensation. She was granted 9,807 shares of common stock in the form of a time-based restricted stock unit (RSU) award, bringing her total direct holdings to 28,861 common shares.
She was also granted stock options covering 46,600 shares of common stock at an exercise price of $7.01 per share. Both the RSU and the option award are scheduled to vest on May 29, 2027, subject to her continuous service with REGENXBIO. The options expire on May 29, 2036.